129 related articles for article (PubMed ID: 26545383)
1. L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells.
Mendes J; Gonçalves AC; Alves R; Jorge J; Pires A; Ribeiro A; Sarmento-Ribeiro AB
Pathol Oncol Res; 2016 Apr; 22(2):301-9. PubMed ID: 26545383
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
4. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
5. Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma.
Wu K; Sun XQ; Wang CQ; Gao TX; Sun P; Wang Y; Jiang WQ; Li ZM; Huang JJ
Cancer Med; 2019 Aug; 8(10):4688-4698. PubMed ID: 31218841
[TBL] [Abstract][Full Text] [Related]
6. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
[TBL] [Abstract][Full Text] [Related]
7. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
8. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Bernasconi E; Gaudio E; Lejeune P; Tarantelli C; Cascione L; Kwee I; Spriano F; Rinaldi A; Mensah AA; Chung E; Stathis A; Siegel S; Schmees N; Ocker M; Zucca E; Haendler B; Bertoni F
Br J Haematol; 2017 Sep; 178(6):936-948. PubMed ID: 28653353
[TBL] [Abstract][Full Text] [Related]
10. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
11. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
12. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
13. Identification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells.
Bhatti IA; Abhari BA; Fulda S
Cancer Lett; 2017 Oct; 405():63-72. PubMed ID: 28716527
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas.
Hayden RE; Kussaibati R; Cronin LM; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2015 Apr; 56(4):1079-87. PubMed ID: 24996440
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
[TBL] [Abstract][Full Text] [Related]
17. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines.
Sánchez-Hidalgo M; Lee M; de la Lastra CA; Guerrero JM; Packham G
J Pineal Res; 2012 Nov; 53(4):366-73. PubMed ID: 22582944
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
[TBL] [Abstract][Full Text] [Related]
19. Histamine-releasing factor/translationally controlled tumor protein plays a role in induced cell adhesion, apoptosis resistance and chemoresistance in non-Hodgkin lymphomas.
He S; Huang Y; Wang Y; Tang J; Song Y; Yu X; Ma J; Wang S; Yin H; Li Q; Ji L; Xu X
Leuk Lymphoma; 2015 Jul; 56(7):2153-61. PubMed ID: 25363345
[TBL] [Abstract][Full Text] [Related]
20. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
